Target selection issues in drug discovery and development

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 16-18

  Sausville, E A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cancer treatment; Drug target; Oncogene

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER THERAPY; CONFERENCE PAPER; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG TARGET; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; MICROENVIRONMENT; MICROENVIRONMENTAL TARGET; NONHUMAN; ONCOGENE; ONTOGENIC TARGET; ONTOGENY; PATHOLOGICAL TARGET; PATHOLOGY; PHARMACOLOGICAL TARGET; PHARMACOLOGY; THERAPEUTIC INDEX; TUMOR MICROENVIRONMENT;

EID: 11244302579     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.16     Document Type: Conference Paper

References (8)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57.
2. Gray JH, Mangravite LM, Owen RP et al. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004; 65: 512.
3. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88 (5): 259-69.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335.
5. Mayer RJ. Two steps forward in the treatment of colorectal cancer. N Engl J Med. 2004; 350: 2406.
6. Elkin M, Reich R, Nagler A et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000; 14: 2477.
7. Dancey J, Sausville EA Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Disc 2003; 2: 296.
8. Adams J, Kauffman M Development of the proteosome inhibitor velcade (Bortezomib). Cancer Invest 2004; 22: 304.